National Advisory Committee on Immunization (NACI): Workplan

Canadian Immunization Guide

PDF version (292 KB, 2 pages)

Preamble

The following represents the National Advisory Committee on Immunization's planned work for the 2020-2021 fiscal year (April 2020 to March 2021). These projects will not necessarily be completed within the fiscal year. This workplan may be reassessed based on emerging public health needs. Triggers for the activation of Working Groups (WGs) and the development of new NACI guidance documents, or the adoption of new priorities may include the following:

Workplan

2020-2021
Initiative Issue(s) Triggers Expected date of completion*
COVID-19 Updated guidance on priority immunization strategies and associated key populations based on current evidence and authorized COVID-19 vaccines. Public health emergency Q3 2020-2021
Updated recommendations on the use of authorized COVID-19 vaccines as they are approved for use in Canada, and as evidence on these vaccines and COVID-19 evolves. New vaccine 2021 for final guidance, pending clinical trial progression
Hepatitis A Consider a universal hepatitis A vaccine schedule, including 1-dose option. Recommendation adoption by reputable organization On hold for COVID-19
Measles, Mumps, Rubella (MMR) Additional dose of mumps-containing vaccine in outbreaks Changes in disease epidemiology 2021
Full CIG Chapter Update for Measles, Mumps and Rubella due CIG Chapter reviews due 2021
Pertussis Optimal timing of adult and adolescent Tdap boosters, inlcuding Td intervals New indication On hold for COVID-19
Pneumococcal Consider recommendations for PCV10 in light of new indications and practice New indication On hold for COVID-19
Rabies Updated guidance on rabies vaccine PrEP and PEP in context of new guidance from WHO Recommendation adoption by reputable organization 2021
Full CIG chapter review due CIG Chapter review due 2021
Smallpox Update smallpox vaccine guidance for lab workers and outbreak situations, including monkeypox New vaccine On hold for COVID-19
Seasonal Influenza Seasonal Influenza statement New vaccine 2020-21
Consider dose-sparing strategies, including intradermal administration Prevention of vaccine supply issues Q2 2020-2021
Minimum observation time following influenza vaccination, in context of COVID-19 Recommendation adoption by reputable organization Q2 2020-2021
Optimal timing of seasonal influenza vaccine programs (including intra-season waning) P/T programmatic concerns 2022
Analysis of product choices for adults 65+ P/T programmatic concerns 2021
Repeated Vaccination P/T programmatic concerns 2020
Review of safety and effectiveness of influenza vaccine in pregnancy Publication of key studies 2021
CIG: Part 1 (Key immunization information) Routine chapter updates (5): Benefits of Immunization, National Guidelines for Immunization Practices, Communicating Effectively about Immunization, Principles of Vaccine Interchangeability, Blood Products, Human Immune Globulin and Timing of Immunization CIG Chapter reviews due 2021
CIG : Part 2 ( Vaccine Safety) Routine Chapter updates (3) CIG Chapter reviews overdue 2019-20
CIG: Part 4: Active Vaccines Routine chapter updates (13): BCG, Diphtheria, Hep A, Hib, MMR, Polio, Pneumococcal, Rotavirus, Rabies, Smallpox, Tetanus, Varicella, Yellow Fever CIG Chapter reviews due and some overdue On hold for COVID-19
Evidence-based methods Transition to GRADE methodology Recommendation adoption by reputable organization On hold for COVID-19
NACI economics framework Incorporation into NACI process: economics framework Recommendation adoption by reputable organization 2021
Economic guidelines Incorporation into NACI process: economic guidelines Recommendation adoption by reputable organization 2022
*Please note that this workplan is evergreen. As new products and indications are authorized or new information becomes available, workplan items may be added for consideration and priorities may change.
Abbreviations:
NACI National Advisory Committee on Immunization
BCG Bacillus Calmette-Guérin
CATMAT Committee to Advise on Tropical Medicine and Travel
CCDR Canada Communicable Disease Report
CIC Canadian Immunization Committee
CIG Canadian Immunization Guide
CPS Canadian Paediatric Society
EEFA Ethics, Equity, Feasibility, Acceptability
FY Fiscal year (April 1 - March 31)
JE Japanese encephalitis
NoC Notice of compliance
P/Ts Provinces and territories
QIV Quadrivalent influenza vaccine
SOGC Society of Obstetricians and Surgeons of Canada
TIV Trivalent influenza vaccine
TOR Terms of reference
WG Working group
WHO World Health Organization
YF Yellow fever
2019-2020
Initiative Issue(s) Triggers Expected date of completion*
Ebola Virus Disease Interim pre-market guidance on domestic use of stockpiled investigational vaccine for ring vaccination strategy in event of imported cases, post-market guidance to follow in later years New vaccine Q2 2019 for interim guidance
Hepatitis A Consider a universal hepatitis A vaccine schedule, including 1-dose option Recommendation adoption by reputable organization 2021
Measles, Mumps, Rubella (MMR) Consider additional dose of mumps-containing vaccine in outbreaks Changes in disease epidemiology 2019-20
Full CIG chapter update for Measles, Mumps and Rubella due CIG chapter reviews due 2019-20
Pertussis Optimal timing of adult and adolescent Tdap boosters, including Td intervals P/T programmatic concerns 2020
Pneumococcal Evaluation of preferential PCV13 recommendation for routine infant programs Recommendation adoption by reputable organization 2020
Rabies Updated guidance on rabies vaccine PrEP and PEP in context of new guidance from WHO Recommendation adoption by reputable organization 2020
Full CIG chapter review due CIG chapter review due 2020
Respiratory Syncytial Virus (RSV) Review/update NACI guidance on Palivizumab Recommendation adoption by reputable organization 2019-20
CIG - chapter creation   2019-20
Seasonal Influenza Seasonal influenza New vaccine 2020-21
New Products: quadrivalent influenza vaccines New vaccine 2020-21 (dependant on NOC)
Repeated vaccination P/T programmatic concerns 2020
CIG: Part 1 (Key immunization information) Routine chapter updates (6): Immunization in Canada. Benefits of Immunization, National Guidelines for Immunization Practices, Communicating Effectively about Immunization, Principles of Vaccine Interchangeability, Blood Products, Human Immune Globulin and Timing of Immunization CIG chapter reviews due 2019-20
CIG : 
Part 2: Vaccine Safety
Routine chapter updates (3) CIG chapter reviews overdue 2019-20
CIG: Part 3: Special Populations Routine chapter updates (6): Immunization of Adults, Immunization of Persons with Inadequate Immunization Records, Immunization of Infants Born Prematurely, Immunization of Patients in Healthcare Institutions, Immunization of Persons New to Canada, Immunization of Workers CIG chapter reviews overdue 2019-20
CIG: Part 4: Active Vaccines Routine chapter updates (12): BCG, Diphtheria, Hib, MMR, Polio, Rabies, Smallpox, Tetanus, YF, JE CIG chapter reviews due and some overdue 2019-20
Ethics, Equity, Feasibility, Acceptability (EEFA) Incorporation into NACI process: EEFA Recommendation adoption by reputable organization 2019
NACI economics framework Incorporation into NACI process: economics framework Recommendation adoption by reputable organization 2020
Economic guidelines Incorporation into NACI process: economic guidelines Recommendation adoption by reputable organization 2021

*Please note that this workplan is evergreen. As new products and indications are authorized or new information becomes available, workplan items may be added for consideration and priorities may change.

Abbreviations:

NACI

National Advisory Committee on Immunization

BCG

Bacillus Calmette-Guérin

CATMAT

Committee to Advise on Tropical Medicine and Travel

CCDR

Canada Communicable Disease Report

CIC

Canadian Immunization Committee

CIG

Canadian Immunization Guide

CPS

Canadian Paediatric Society

EEFA

Ethics, Equity, Feasibility, Acceptability

FY

Fiscal year (April 1 - March 31)

Hib

Haemophilus influenzae type b

JE

Japanese encephalitis

NoC

Notice of compliance

PCV13

Pneumococcal conjugate vaccine

PEP

Post-exposure prophylaxis

PrEP

Pre-exposure prophylaxis

P/Ts

Provinces and territories

QIV

Quadrivalent influenza vaccine

SOGC

Society of Obstetricians and Surgeons of Canada

Td

Tetanus and diphtheria vaccine

Tdap

Tetanus, diphtheria and pertussis vaccine

TIV

Trivalent influenza vaccine

TOR

Terms of reference

WG

Working group

WHO

World Health Organization

YF

Yellow fever

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: